Nemaura推出与GLP
Company CEO to discuss development at 1pm EST on 15th November 2023, at the Sidoti Virtual Investor Conference Loughborough, UK, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, developer of a daily wear non-invasive glucose sensor, and digital healthcare programs today announced the UK launch of its ground-breaking approach to metabolic health and weight management by integrating continuous glucose monitoring (CGM) with its behavioral change program, Miboko, complemented by pharmaceutical interventions using GLP-1 agonists such as Ozempic, Wegovy and Mounjaro.
公司首席执行官将于2023年11月15日在英国拉夫堡的Sidoti虚拟投资者会议上于2023年11月14日（GLOBE NEWSWIRE）于1pm EST讨论开发-Nemaura Medical，日常佩戴无创葡萄糖传感器的开发人员，今天，数字医疗保健计划宣布英国通过将连续血糖监测（CGM）与其行为改变计划Miboko相结合，采用突破性的代谢健康和体重管理方法，辅之以使用GLP-1激动剂（如Ozempic）的药物干预，Wegovy和Mounjaro。
This innovative offering, featuring education, lifestyle modifications, dietary guidance, exercise goals, and cutting-edge glucose monitoring, represents a significant advancement in personalized weight loss strategies addressing the metabolic health, obesity and diabetes markets. Nemaura's program leverages the power of its world-first daily wear non-invasive CGM technology, allowing individuals to gain insights into how their body deals with glucose.
这项创新服务以教育，改变生活方式，饮食指导，锻炼目标和尖端血糖监测为特色，代表了针对代谢健康，肥胖和糖尿病市场的个性化减肥策略的重大进步。Nemaura的计划利用了世界上首屈一指的非侵入性CGM技术的力量，使个人能够深入了解他们的身体如何处理葡萄糖。
By using CGM for just two days per month, participants can access real-time data on how the drugs, lifestyle, diet, and exercise are impacting their blood glucose profiles, empowering them to make informed choices for sustainable improvements to quality of life. In pilot studies with the UK's National Health Service (NHS), Nemaura's program has demonstrated encouraging outcomes.
通过每月仅使用CGM两天，参与者可以访问有关药物，生活方式，饮食和运动如何影响其血糖状况的实时数据，使他们能够为可持续改善生活质量做出明智的选择。在英国国家卫生服务（NHS）的试点研究中，Nemaura的计划显示出令人鼓舞的结果。
Early results indicate positive responses to the integrated approach even in the absence of drug therapy using GLP-1’s, showcasing the program's potential to reshape the landscape of personalized health solutions. The integration of behaviour change programs, encompassing education on nutrition, personalized exercise regimens, and lifestyle adjustments, complements the data-driven appro.
即使在没有使用GLP-1的药物治疗的情况下，早期结果也表明对综合方法的积极响应，展示了该计划重塑个性化健康解决方案的潜力。行为改变计划的整合，包括营养教育，个性化锻炼方案和生活方式调整，补充了数据驱动的APPO。
相关知识
康宝莱推出GLP
“药王”的黄昏与GLP
GLP
亦餐GLP
大涨407%，GLP
ZOEYNUO GLP
国产GLP
GLP成分
4款GLP
国内市场GLP
网址: Nemaura推出与GLP https://m.trfsz.com/newsview797516.html
